Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits

Perfusion

Volumn 19, Issue 5, 2004, Pages 283-288

  Young, Guy ^a   Yonekawa, Karyn E ^a   Nakagawa, Peggy ^a   Nugent, Diane J ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; D DIMER; HEPARIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBIN INHIBITOR;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG EFFICACY; EXTRACORPOREAL OXYGENATION; HEMATOLOGICAL PARAMETERS; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; THROMBOGENESIS;

BIOLOGICAL MARKERS; BLOOD COAGULATION TESTS; EQUIPMENT FAILURE; EXTRACORPOREAL MEMBRANE OXYGENATION; HEPARIN; HUMANS; PIPECOLIC ACIDS; THROMBELASTOGRAPHY; THROMBIN; THROMBOSIS;

EID: 4043134885     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1191/0267659104pf759oa     Document Type: Article

References (24)

1. Kim ES, Stolar CJ. ECMO in the newborn. Am J Perinatol 2000; 17: 345-56.
2. Rais-Bahrami K, Short BL. The current status of neonatal extracorporeal membrane oxygenation. Semin Perinatol 2000; 24: 406-17.
3. Arnold P, Jackson S, Wallis J, Smith J, Bolton D, Haynes S. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med 2001; 27: 1395-400.
4. Hardart GE, Fackler CJ. Predictors of intracranial hemorrhage during neonatal extracorporeal membrane oxygenation. J Pediatr 1999; 134: 156-59.
5. McManus ML, Kevy SV, Bower LK, Hickey PR. Coagulation factor deficiencies during initiation of extracorporeal membrane oxygenation. J Pediatr 1995; 126: 900-904.
6. Urlesberger B, Zobel G, Zenz W et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 1996; 129: 264-68.
7. Vieira A, Berry L, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991; 63: 85-98.
8. Schmidt B, Ofosu FA, Mitchell L, Brooker LA, Andrew M. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-408.
9. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 1994; 72: 836-42.
10. Weitz JI. Low-molecular weight heparins. N Eng J Med 1997; 337: 688-98.
11. Turpie AGG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N Eng J Med 2001; 344: 619-25.
12. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12: 1-12.
13. Greinacher A, Eichler P, Lubenow N, Kwasny J, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846-51.
14. Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 2000; 12: 41-52.
15. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-43.
16. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002; 57: 177-84.
17. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol/ Oncol Clin N Am 2000; 14: 445-57.
18. Johnston N, Wait M, Huber L. Argatroban in adult extracorporeal membrane oxygenation. J Extra Corp Technol 2002; 34: 281-84.
19. Lubenow N, Selleng S, Wollert HG, Eichler P, Mullejans B, Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003; 75: 577-79.
20. Edwards JT, Hamby JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass: heparin-induced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg 2003; 75: 1622-24.
21. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237-46.
22. ECLS Registry Report. January 2002. Retrieved from: www.elso.med.umich.edu
23. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001; 119: 64-94.
24. Francis J. Laboratory investigation of hypercoagulability. Semin Thromb Hemost 1998; 24: 111-26.